Physician profile
Ebony Ojemi
NPI 1740049964
$1,859.12
in general payments reported to CMS, 2019-2025
11 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $209 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.63 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $443.67 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $440.74 | 2024-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $367.11 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $200.24 | 2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $95.54 | 2025 | Auvelity |
| Alkermes, INC. | $80.82 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $75.24 | 2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $65.38 | 2025 | Cobenfy |
| Lundbeck LLC | $47.71 | 2024 | Rexulti |
| Corium, LLC | $26.45 | 2025 | Azstarys |
| Lilly USA, LLC | $16.22 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebony Ojemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.